

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC,
MYLAN PHARMACEUTICALS INC., MYLAN INC.,
Petitioner,

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
BAUSCH & LOMB PHARMA HOLDINGS CORP.
Patent Owner.

Case IPR2015-00902
Patent 8,669,290 B2

Filed: April 1, 2016

Petitioner's Updated Exhibit List

I. INTRODUCTION

Pursuant to 37 C.F.R. § 42.63(e), Petitioners InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC, Mylan Pharmaceuticals Inc., Mylan Inc., Lupin Ltd., (collectively “Petitioners”) hereby submit a current listing of Petitioner Exhibits to counsel for Patent Owner Senju Pharmaceutical Co., Ltd., Bauch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp. (collectively “Patent Owner”).

<i>Exhibit #</i>	<i>Description</i>
1001	Sawa <i>et al.</i> , U.S. Patent No. 8,669,290, “Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid”
1002	Certified English translation of: Hara, Yoshiyuki , “Bromfenac sodium hydrate,” <i>Clinics & Drug Therapy</i> 19:1014-1015 (2002)
1003	Declaration of Paul A. Laskar, Ph.D.
1004	Ogawa <i>et al.</i> , U.S. Patent No. 4,910,225 “Locally Administrable Therapeutic Composition for Inflammatory Disease”
1005	Desai <i>et al.</i> , U.S. Patent No. 5,603,929, “Preserved Ophthalmic Drug Compositions Containing Polymeric Quaternary Ammonium Compounds”
1006	Desai, <i>et al.</i> , U.S. Patent No. 5,558,876, “Topical Ophthalmic Acidic Drug Formulations”
1007	Certified English translation of “Bromfenac sodium hydrate” in the <i>Japanese Pharmacopoeia 2001 Edition: 27-29</i> , Yakuji Nippo Limited (2001)
1008	FDA approved “BROMDAY™ (bromfenac ophthalmic solution, .09%) Product Label,” U.S. Approval: March 24, 2005, ISTA Pharmaceuticals, Inc.
1009	Sallmann <i>et al.</i> , U.S. Patent No. 6,107,343, “Ophthalmic And Aural Compositions Containing Diclofenac Potassium”
1010	Guttman <i>et al.</i> , “Solubilization of Anti-inflammatory steroids by Aqueous Solutions of Triton-WR-1339,” <i>Journal of Pharmaceutical Sciences</i> 50: 305-307 (1961)

1011	Fu <i>et al.</i> , Australian Patent No. AU-B-22042/88, “Preservative System For Ophthalmic Formulations”
1012	Yasueda <i>et al.</i> , U.S. Patent No. 6,274,609, “Aqueous Liquid Pharmaceutical Composition Containing as Main Component Benzopyran Derivative”
1013	“Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations,” Appl. No. N203168, U.S. FDA, accessed at http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=203168&Product_No=001&table1=0B_Rx
1014	“Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations,” Appl. No. N203168, Active Ingredient Bromfenac Sodium, accessed at http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?App1_No=203168&TABLE1=0B_Rx , last accessed on January 24, 2014
1015	Reserved
1016	Reserved
1017	Kapin, <i>et al.</i> , International Patent No. WO 2002/13804, “Method for Treating Angiogenesis-Related Disorders Using Benzoyl Phenylacetic Acid”
1018	Flach, Allan., “Topical Nonsteroidal Antiinflammatory Drugs for Ophthalmic Uses,” <i>Ophthalmic NSAIDs: 77-83</i> (1996)
1019	Schott, H., “Comparing the Surface Chemical Properties and the Effect of Salts on the Cloud Point of a Conventional Nonionic Surfactant, Octoxynol 9 (Triton X-100), and of Its Oligomer, Tyloxapol (Triton WR-1339),” <i>Journal of Colloid and Interface Science</i> 205: 496-502 (1998)
1020	Regev, O., <i>et al.</i> , “Aggregation Behavior of Tyloxapol, a Nonionic Surfactant Oligomer, in Aqueous Solution,” <i>Journal of Colloid and Interface Science</i> 210: 8-17 (1999)
1021	Aviv, H., International Patent No. WO 94/05298, “Submicron Emulsions as Ocular Drug Delivery Vehicles”
1022	Bergamini <i>et al.</i> , U.S. Patent No. 5,597,560, “Diclofenac And Tobramycin Formulations For Ophthalmic And Otis Topical Use”
1023	U.S. Patent Application No. 13/687,242, Applicant Remarks in support of amendment, November 28, 2012
1024	Reserved

1025	U.S. Patent Application No. 13/687,242, Applicant Arguments/Remarks Made in an Amendment, 10/22/2013, pp. 9-15
1026	"monohydrate," Webster's New World Dictionary of the American Language: 920, New World Dictionaries / Simon and Schuster (1980).
1027	"Voltaren," Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Appl. No. N020037, U.S. FDA, accessed at http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?AppplNo=020037&TABLE1=OB_Rx
1028	Yanni et al., U.S. Patent No. 5,475,034, "Topically Administrable Compositions Containing 3-Benzoylphenylacetic Acid Derivatives for Treatment of Ophthalmic Inflammatory Disorders".
1029	"ISTA Pharmaceuticals Submits New Drug Application for Xibrom™ QD (once-daily), News Release, ISTA Pharmaceuticals (December 20, 2007)
1030	Prince, S., <i>et al.</i> , "Analysis of benzalkonium chloride and its homologs: HPLC versus HPCE," <i>Journal of Pharmaceutical and Biomedical Analysis</i> 19: 877-882, Elsevier Science B.V., Netherlands (1999)
1031	"Acular®" and "Azopt™," Physician's Desk Reference 54: 486-487, 491-492 (2000).
1032	Doughty, M., "Medicines Update for optical practitioners- Part 11," <i>Optician</i> 5853 (223), (2002).
1033	Reddy, Indra K., <i>Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach</i> : 42-43, 390 (1996).
1034	Fan, T., "Determination of Benzalkonium Chloride in Ophthalmic Solutions Containing Tyloxapol by Solid-Phase Extraction and Reversed-Phase High-Performance Liquid Chromatography," <i>Journal of Pharmaceutical Sciences</i> 82 (11): 1172-1174, American Pharmaceutical Association, United States (1993).
1035	Wong, Michelle, International Patent No. WO 94/15597, "Ophthalmic Compositions Comprising Benzyl lauryldimethylammonium Chloride" (filed January 11, 1993; issued July 21, 1994).
1036	Guy et al., U.S. Patent No. 5,540,930, "Suspension of Loteprednol Etabonate for Ear, Eye, or Nose Treatment" (filed October 25, 1993; issued July 30, 1996).

1037	FDA approved "ALREXTM (loteprednol etabonate ophthalmic suspension) 0.2% Product Label," U.S. Approval: 1998, Bausch & Lomb Pharmaceuticals.
1038	FDA approved "LOTEMAXTM (loteprednol etabonate ophthalmic suspension) 0.5% Product Label," U.S. Approval: 1998, Bausch & Lomb Pharmaceuticals.
1039	"TOBRADEX®" Physician's Desk Reference 54: 490 (2000).
1040	"Alomide® 0.1%" Physician's Desk Reference 50: 469 (1996).
1041	Johnson, R., et al., U.S. Patent No. 2,880,130, "Anti-Inflammatory Steroid Solutions".
1042	Johnson, R., et al., U.S. Patent No. 2,880,138, "Anti-Inflammatory Steroid Solutions".
1043	Kawabata et al., Canadian Patent No. CA 2 383 971 A1, "Prophylactic and Therapeutic Medicaments for Ophthalmic Uses".
1044	Patani, G., et al., "Bioisoterism: A Rational Approach in Drug Design," Chem. Rev. 96: 3147-3176 (1996).
1045	FDA approved "XIBROMTM (bromfenac ophthalmic solution, .09%) Product Label," ISTA Pharmaceuticals, Inc.
1046	Senju Pharmaceutical Co., Ltd. Press Releases, "The approval of BRONUCK® (bromfenac sodium hydrate ophthalmic solution) as an import drug in China," http://www.senju.co.jp/ , accessed at http://www.senju.co.jp/english/news/_icsFiles/afieldfile/2009/11/18/2009111814br.pdf , published November 17, 2009, 1 page.
1047	FDA approved "PROLENSATM (bromfenac ophthalmic solution, 0.07%) Product Label," U.S. Approval: April 5, 2013, Bausch & Lomb Incorporated
1048	"Borax (Sodium tetraborate)," Biochemicals and Reagents: 175, Sigma-Aldrich (2000-2001).
1049	Ali, et al., U.S. Patent No. 6,071,904, "Process for Manufacturing Ophthalmic Suspensions".
1050	Story, M., et al., European Patent No. 0274870, "Micelles containing a non-steroidal antiinflammatory compound" (filed December 12, 1987; issued July 7, 1988)
1051	"DuractTM," Physician's Desk Reference 52:3035-3037 (1998).
1052	Curriculum Vitae of Paul A. Laskar, Ph.D.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.